Ad disclosure
Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
Biogen Inc. (NASDAQ:BIIB)
Stock Price:
$289.13
-4.07
(-1.39%)
Updated
Sep 24, 2021 01:45 PM GMT+0000
Overview
Financials
Statistics
Profile
Chart
| Market Cap | 43.09B |
|---|---|
| Revenue | 11.70B |
| Gross Profit | 9.82B |
| Shares Out | 149.03M |
| EPS (ttm) | 12.5 |
| PE Ratio | 22.7812 |
| Forward PE | 10.2607 |
| Dividend Rate (ttm) | 0.0000 |
| Dividend Yield | 0.0000 |
| Trading Day | Sep 24 |
|---|---|
| Last Price | $289.13 |
| Previous Close | $293.20 |
| Change ($) | -4.07 |
| Change (%) | -1.39% |
| Day's Open | 289.13 |
| Day's Range | 289.13 - 291.215 |
| Day's Volume | 76.13K |
| 52 Week Range | 223.25 - 468.55 |
About
Country
United States
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Employees
9,100
CEO
George Scangos
Address
225 Binney St
Cambridge
Massachusetts
02142-1031
Cambridge
Massachusetts
02142-1031
Phone
17814642000
Website
www.biogen.com
Ticker Symbol
BIIB
Exchange
NASDAQ Stock Exchange
Reporting Currency
USD
Biogen Inc. earnings reports (2020)
| Q3 2020 | Q2 2020 | Q1 2020 | Q1 2020 | |
|---|---|---|---|---|
| Actual EPS | 8.84 | 10.26 | 9.14 | 9.14 |
| Consensus EPS | 8.09 | 8.02 | 7.72 | 7.72 |
| Announce Time | BTO | BTO | BTO | BTO |
| Number of Estimates | 29 | 27 | 27 | 27 |
| EPS Surprise Dollar | 0.75 | 2.24 | 1.42 | 1.42 |
| EPS Report Date | 21-10-2020 | 22-07-2020 | 21-04-2020 | 21-04-2020 |
| Fiscal End Date | 30-09-2020 | 30-06-2020 | 30-03-2020 | 30-03-2020 |
| Year Ago | 9.17 | 9.15 | 6.98 | 6.98 |
| Year Ago % Change | -3.6% | 12.13% | 30.95% | 30.95% |
Biogen Inc. earnings reports (2019)
| Q4 2019 | Q3 2019 | Q2 2019 | |
|---|---|---|---|
| Actual EPS | 8.34 | 9.17 | 9.15 |
| Consensus EPS | 8.03 | 8.3 | 7.53 |
| Announce Time | BTO | BTO | BTO |
| Number of Estimates | 28 | 24 | 27 |
| EPS Surprise Dollar | 0.31 | 0.87 | 1.62 |
| EPS Report Date | 30-01-2020 | 21-10-2019 | 22-07-2019 |
| Fiscal End Date | 31-12-2019 | 29-09-2019 | 29-06-2019 |
| Year Ago | 6.99 | 7.4 | 5.8 |
| Year Ago % Change | 19.31% | 23.92% | 57.76% |
Biogen Inc. income statements (2020) (USD)
| October 2020 | September 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|---|
| Total Revenue | 3.38B | 3.12B | 3.40B | 3.16B | 3.16B |
| Cost of Revenue | 449.10M | 563.90M | 523.90M | 561.20M | 561.20M |
| Gross Profit | 2.93B | 2.56B | 2.88B | 2.60B | 2.60B |
| Research & Development | 1.14B | 1.09B | 596.30M | 427.90M | 427.90M |
| Selling General & Admin | 573.10M | 573.10M | 541.10M | 570.10M | 570.10M |
| Operating Expense | 2.32B | 2.23B | 1.66B | 1.56B | 1.56B |
| Operating Income | 1.06B | 892.50M | 1.74B | 1.60B | 1.60B |
| Other Income Expense Net | 0 | 65.30M | 296.80M | 101.90M | 101.90M |
| EBIT | 1.04B | 892.50M | 1.74B | 1.60B | 1.60B |
| Interest Income | 50.30M | 56.30M | 56.60M | 44.30M | 44.30M |
| Pretax Income | 0.94B | 0.96B | 2.04B | 1.70B | 1.70B |
| Income Tax | 240.80M | 240.80M | 446.10M | 292M | 292M |
| Minority Interest | 2.40M | 2.40M | 64.40M | -6.5M | -6.5M |
| Net Income | 701.50M | 701.50M | 1.54B | 1.40B | 1.40B |
| Net Income Basic | 701.50M | 701.50M | 1.54B | 1.40B | 1.40B |
Biogen Inc. income statements (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Total Revenue | 3.26B | 3.17B | 3.21B | 3.08B |
| Cost of Revenue | 560M | 498M | 546.40M | 670.20M |
| Gross Profit | 2.70B | 2.67B | 2.66B | 2.41B |
| Research & Development | 646.50M | 540.40M | 484.80M | 563.70M |
| Selling General & Admin | 664.90M | 554.50M | 587.60M | 567.70M |
| Operating Expense | 1.87B | 1.59B | 1.62B | 1.80B |
| Operating Income | 1.39B | 1.58B | 1.59B | 1.28B |
| Other Income Expense Net | 343.20M | 201M | 171.30M | 581.10M |
| EBIT | 1.39B | 1.58B | 1.59B | 1.28B |
| Interest Income | 46M | 45.80M | 47.70M | 47.90M |
| Pretax Income | 1.73B | 1.78B | 1.76B | 1.86B |
| Income Tax | 276.10M | 211.30M | 248.10M | 422.50M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | 1.44B | 1.55B | 1.49B | 1.41B |
| Net Income Basic | 1.44B | 1.55B | 1.49B | 1.41B |
Biogen Inc. income statements (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Total Revenue | 3.15B | 3.09B | 3B | 2.82B |
| Cost of Revenue | 565.80M | 553.40M | 528.40M | 549.90M |
| Gross Profit | 2.58B | 2.54B | 2.47B | 2.27B |
| Research & Development | 611.60M | 507.90M | 0.98B | 496.70M |
| Selling General & Admin | 580.20M | 497.70M | 516.20M | 501.30M |
| Operating Expense | 1.76B | 1.56B | 2.03B | 1.55B |
| Operating Income | 1.39B | 1.53B | 0.97B | 1.27B |
| Other Income Expense Net | 23.80M | 282.60M | 204.30M | 226.30M |
| EBIT | 1.39B | 1.53B | 0.97B | 1.27B |
| Interest Income | 49.40M | 49M | 51.70M | 50.50M |
| Pretax Income | 1.41B | 1.81B | 1.18B | 1.49B |
| Income Tax | 469.60M | 369.80M | 263.70M | 322.50M |
| Minority Interest | -1.9M | -1.5M | 48.40M | -1.7M |
| Net Income | 0.95B | 1.44B | 866.60M | 1.17B |
| Net Income Basic | 0.95B | 1.44B | 866.60M | 1.17B |
Biogen Inc. income statements (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Total Revenue | 3B | 2.77B | 2.73B |
| Cost of Revenue | 617.80M | 478.90M | 483.70M |
| Gross Profit | 2.39B | 2.29B | 2.24B |
| Research & Development | 587.60M | 446.40M | 796.20M |
| Selling General & Admin | 553.90M | 433.80M | 430.20M |
| Operating Expense | 1.76B | 1.36B | 1.71B |
| Operating Income | 1.24B | 1.41B | 1.02B |
| Other Income Expense Net | 155M | 197.50M | 114.60M |
| EBIT | 1.24B | 1.41B | 1.02B |
| Interest Income | 56.80M | 61.80M | 63.60M |
| Pretax Income | 1.40B | 1.61B | 1.13B |
| Income Tax | 1.57B | 383.80M | 269.60M |
| Minority Interest | 131.10M | 0 | 0 |
| Net Income | -297.4M | 1.23B | 862.80M |
| Net Income Basic | -297.4M | 1.23B | 862.80M |
Biogen Inc. balance sheet (2020) (USD)
| October 2020 | September 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|---|
| Current Cash | 3.58B | 2.22B | 2.38B | 2.59B | 2.59B |
| Receivables | 2.55B | 2.55B | 2.57B | 2.60B | 2.60B |
| Inventory | 1.03B | 1.03B | 0.95B | 858.80M | 858.80M |
| Current Assets | 7.84B | 7.84B | 8.49B | 8.01B | 8.01B |
| Other Current Assets | 683.50M | 683.50M | 638.80M | 683.80M | 683.80M |
| Short Term Investments | 683.50M | 1.36B | 1.94B | 1.27B | 1.27B |
| Long Term Investments | 17.09B | 2.50B | 2.29B | 1.84B | 1.84B |
| Property/Plant Equipment | 3.36B | 3.79B | 3.77B | 3.70B | 3.70B |
| Good Will | N.A | N.A | N.A | N.A | N.A |
| Intangible Assets | 3.32B | 3.32B | 3.38B | 3.45B | 3.45B |
| Tangible Assets (Net) | 1.68B | -9.15B | -8.59B | -7.36B | -7.36B |
| Other Assets | 1.83B | 349.70M | 116.90M | 263.10M | 263.10M |
| Total Assets | 24.93B | 24.93B | 25.51B | 26.12B | 26.12B |
| Accounts Payable | 398.40M | 398.40M | 383.90M | 389M | 389M |
| Other Current Liabilities | 3.41B | 3.29B | 2.49B | 2.44B | 2.44B |
| Total Current Liabilities | 3.80B | 3.80B | 3.45B | 4.64B | 4.64B |
| Total Liabilities | 14.18B | 14.19B | 14.22B | 13.58B | 13.58B |
| Long Term Debt | 7.43B | 7.83B | 7.84B | 4.86B | 4.86B |
| Current Long Term Debt | 0 | N.A | N.A | 1.50B | 1.50B |
| Minority Interest | -14M | 2.40M | 64.40M | -6.5M | -6.5M |
| Common Stock | 100K | 153.90M | 158.30M | 167.30M | 167.30M |
| Treasury Stock | -2.98B | 2.98B | 2.98B | 2.98B | 2.98B |
| Retained Earnings | 13.96B | 13.96B | 14.47B | 15.67B | 15.67B |
| Capital Surplus | N.A | N.A | N.A | 100K | 100K |
| Shareholder Equity | 10.76B | 10.76B | 11.31B | 12.55B | 12.55B |
| Other Liabilities | N.A | N.A | N.A | N.A | N.A |
Biogen Inc. balance sheet (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Current Cash | 2.91B | 2.34B | 1.72B | 2.24B |
| Receivables | 2.47B | 2.52B | 2.52B | 2.62B |
| Inventory | 804.20M | 751.80M | 776.70M | 770.20M |
| Current Assets | 8.38B | 8.45B | 7.91B | 8.94B |
| Other Current Assets | 631M | 743.20M | 1.66B | 1.65B |
| Short Term Investments | 1.56B | 2.09B | 1.23B | 1.67B |
| Long Term Investments | 2.38B | 2.22B | 1.66B | 2.33B |
| Property/Plant Equipment | 3.67B | 3.56B | 3.51B | 3.46B |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 3.53B | 3.39B | 3.68B | 3.06B |
| Tangible Assets (Net) | -6.58B | -5.7B | -6.97B | -5.18B |
| Other Assets | 278.70M | 836.80M | 0.96B | 0.94B |
| Total Assets | 27.23B | 27.48B | 26.29B | 26.45B |
| Accounts Payable | 530.80M | 382.20M | 377.10M | 378M |
| Other Current Liabilities | 2.69B | 2.36B | 2.41B | 2.53B |
| Total Current Liabilities | 4.86B | 4.43B | 3.21B | 3.15B |
| Total Liabilities | 13.90B | 13.49B | 13.34B | 12.62B |
| Long Term Debt | 4.87B | 4.87B | 6.37B | 6.38B |
| Current Long Term Debt | 1.50B | 1.50B | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 174.20M | 181.90M | 184.80M | 195.20M |
| Treasury Stock | 2.98B | 2.98B | 2.98B | 2.98B |
| Retained Earnings | 16.46B | 17.07B | 16.18B | 17.03B |
| Capital Surplus | N.A | N.A | N.A | N.A |
| Shareholder Equity | 13.34B | 14B | 12.95B | 13.83B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Biogen Inc. balance sheet (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Current Cash | 1.22B | 2.39B | 1.25B | 4.11B |
| Receivables | 2.49B | 2.53B | 2.43B | 2.49B |
| Inventory | 0.93B | 0.92B | 0.93B | 890.80M |
| Current Assets | 7.64B | 8.72B | 7.43B | 10.20B |
| Other Current Assets | 687.60M | 848.30M | 843.30M | 895.90M |
| Short Term Investments | 2.31B | 2.04B | 1.97B | 1.81B |
| Long Term Investments | 2.73B | 1.93B | 1.71B | 1.28B |
| Property/Plant Equipment | 3.60B | 3.54B | 3.41B | 3.33B |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 3.12B | 3.38B | 3.66B | 3.79B |
| Tangible Assets (Net) | -6.1B | -5.18B | -6.34B | -4.05B |
| Other Assets | 333.70M | 322M | 353.10M | 298.50M |
| Total Assets | 25.29B | 25.49B | 23.95B | 26.09B |
| Accounts Payable | 370.50M | 342.30M | 295.70M | 345.80M |
| Other Current Liabilities | 2.86B | 2.58B | 2.63B | 2.57B |
| Total Current Liabilities | 3.30B | 3.17B | 3.15B | 3.15B |
| Total Liabilities | 12.26B | 11.73B | 11.70B | 12.05B |
| Long Term Debt | 5.94B | 5.93B | 5.93B | 5.93B |
| Current Long Term Debt | N.A | N.A | N.A | 3.30M |
| Minority Interest | -1.9M | -1.5M | 48.40M | -1.7M |
| Common Stock | 197.20M | 201.48M | 201.44M | 211.01M |
| Treasury Stock | 2.98B | 2.98B | 2.98B | 2.98B |
| Retained Earnings | 16.26B | 16.94B | 15.50B | 17.33B |
| Capital Surplus | N.A | 47.80M | N.A | N.A |
| Shareholder Equity | 13.04B | 13.77B | 12.26B | 14.05B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Biogen Inc. balance sheet (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Current Cash | 1.57B | 1.55B | 1.17B |
| Receivables | 2.32B | 2.09B | 2.13B |
| Inventory | 0.90B | 1.01B | 0.94B |
| Current Assets | 7.87B | 7.57B | 7.11B |
| Other Current Assets | 0.96B | 0.97B | 1.15B |
| Short Term Investments | 2.12B | 1.96B | 1.72B |
| Long Term Investments | 3.14B | 3.15B | 2.73B |
| Property/Plant Equipment | 3.18B | 3B | 2.83B |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | 3.88B | 4.02B | 4.05B |
| Tangible Assets (Net) | -4.92B | -3.69B | -4.37B |
| Other Assets | 0.94B | 1.22B | 1.17B |
| Total Assets | 23.65B | 23.07B | 21.76B |
| Accounts Payable | 395.50M | 298.70M | 330.30M |
| Other Current Liabilities | 2.90B | 2.46B | 2.44B |
| Total Current Liabilities | 3.37B | 3.45B | 3.38B |
| Total Liabilities | 11.05B | 10.22B | 10.19B |
| Long Term Debt | 5.94B | 5.94B | 5.95B |
| Current Long Term Debt | 3.20M | 573.20M | 559.90M |
| Minority Interest | 131.10M | 0 | 0 |
| Common Stock | 211.50M | 211.48M | 211.43M |
| Treasury Stock | 2.98B | 2.98B | 2.98B |
| Retained Earnings | 15.81B | 16.11B | 14.88B |
| Capital Surplus | 97.80M | 59.20M | 19.30M |
| Shareholder Equity | 12.61B | 12.86B | 11.59B |
| Other Liabilities | N.A | N.A | N.A |
Biogen Inc. cash flow (2020) (USD)
| October 2020 | September 2020 | June 2020 | March 2020 | |
|---|---|---|---|---|
| Net Income | 701.50M | 701.50M | 1.54B | 1.40B |
| Depreciation | 366.80M | 114.70M | 112.90M | 119.90M |
| Changes in Receivables | -22.6M | 22.60M | 29.50M | -133.5M |
| Changes in Inventories | 75M | -82.4M | -126M | -62.2M |
| Cash Change | -747.8M | -160.1M | -206.4M | -322.4M |
| Cash Flow | 4.60B | 1.18B | 1.95B | 1.47B |
| Capital Expenditures | -338.8M | -84.1M | -105M | -261.7M |
| Investments | N.A | 41.90M | -720.4M | 705.10M |
| Investing Activity (other) | N.A | -10.2M | -7.3M | -500K |
| Total Investing Cash Flows | -442.2M | -52.4M | -832.7M | 442.90M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | 3.16B | N.A | 1.47B | N.A |
| Other Financing Cash Flows | N.A | -70.3M | 17.80M | 4.50M |
| Cash Flow Financing | -4.87B | -1.31B | -1.31B | -2.25B |
| Exchange Rate Effect | N.A | 24.10M | -8.8M | 12.70M |
Biogen Inc. cash flow (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Net Income | 1.44B | 1.55B | 1.49B | 1.41B |
| Depreciation | -103M | 329.50M | 117M | 121.10M |
| Changes in Receivables | 45.10M | 1.30M | 98.90M | -130.6M |
| Changes in Inventories | -66.5M | -61.4M | -20.3M | 129M |
| Cash Change | 569.80M | 620.50M | -520.6M | 1.02B |
| Cash Flow | 1.96B | 1.69B | 1.96B | 1.46B |
| Capital Expenditures | -265.4M | -90.1M | -186.9M | -127.1M |
| Investments | 0.94B | -1.2B | 826.20M | 664.20M |
| Investing Activity (other) | 4.60M | -600K | -4M | -300M |
| Total Investing Cash Flows | 708.40M | -365.9M | -110.8M | 238.80M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | N.A | N.A | N.A | N.A |
| Other Financing Cash Flows | -40.2M | 22.20M | 17.20M | 8.70M |
| Cash Flow Financing | -2.12B | -689M | -2.38B | -679.3M |
| Exchange Rate Effect | 17.60M | -19.5M | 1.90M | 400K |
Biogen Inc. cash flow (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Net Income | 0.95B | 1.44B | 866.60M | 1.17B |
| Depreciation | 153M | 157.20M | 171.50M | 168.90M |
| Changes in Receivables | 40.30M | -92.8M | 59.80M | -173.1M |
| Changes in Inventories | -20.2M | 8.20M | -42.7M | 2.60M |
| Cash Change | -1.16B | 1.14B | -2.86B | 2.53B |
| Cash Flow | 1.90B | 1.74B | 1.10B | 1.46B |
| Capital Expenditures | -225.9M | -190.7M | -264.8M | -204.7M |
| Investments | -1.56B | -127.5M | -121.3M | 2.15B |
| Investing Activity (other) | 162.90M | -299.2M | -763.7M | -600M |
| Total Investing Cash Flows | -1.63B | -619.1M | -1.15B | 1.35B |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | N.A | N.A | -3.2M | N.A |
| Other Financing Cash Flows | -84.4M | 25.10M | -38.3M | -18.6M |
| Cash Flow Financing | -1.44B | 25.10M | -2.79B | -268.6M |
| Exchange Rate Effect | 4.80M | -5.4M | -17.1M | -0.9M |
Biogen Inc. cash flow (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Net Income | -297.4M | 1.23B | 862.80M |
| Depreciation | 177.80M | 177.40M | 182.60M |
| Changes in Receivables | -234.1M | 47.60M | -307.1M |
| Changes in Inventories | 75.80M | -85M | -39.1M |
| Cash Change | 25.70M | 378.60M | 245.50M |
| Cash Flow | 1.52B | 1.63B | 1.17B |
| Capital Expenditures | -175.6M | -279.2M | -322.8M |
| Investments | -168M | -669.8M | 420.90M |
| Investing Activity (other) | -425.9M | -297.8M | -300.7M |
| Total Investing Cash Flows | -769.5M | -1.25B | -202.6M |
| Dividends Paid | N.A | N.A | N.A |
| Net Borrowings | -557.7M | -3.2M | N.A |
| Other Financing Cash Flows | -150.4M | -16.3M | 30.80M |
| Cash Flow Financing | -708.1M | -19.5M | -751M |
| Exchange Rate Effect | -15M | 16.60M | 29.90M |
Biogen Inc. dividends (USD)
Total Valuation
Biogen Inc has a market cap or net worth of $43.09 billion. The enterprise value is $47.92 billion.
Market Cap
43.09B
Enterprise Value
47.92B
Important Dates
Earnings Date
Oct 20, 2021
Ex-Dividend Date
n.a
Share Statistics
Biogen Inc has 149.03 million shares outstanding.
Shares Outstanding
149.03M
Float
n.a
Valuation Ratios
The trailing PE ratio is 22.7812 and the forward PE ratio is 10.2607. Biogen Inc's PEG ratio is -0.3600.
PE Ratio
22.7812
Forward PE
10.2607
PS Ratio
3.7400
PB Ratio
4.0600
PEG Ratio
-0.3600
Stock Price Statistics
The stock price has increased by 0.1974%. The beta is 0.0000, so Biogen Inc's price volatility has been lower than the market average.
Beta (1Y)
0.0000
52-Week Price Change
+0.1974%
50-Day Moving Average
326.23
200-Day Moving Average
310.75
Average Volume (30 Days)
1.09M
Income Statement
In the last 12 months, Biogen Inc had revenue of $11.70 billion and earned $9.82 billion in profits. Earnings per share was $12.5.
Revenue
11.70B
Gross Profit
9.82B
EBITDA
3.07B
Earnings per Share
12.5
About
Country
United States
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Employees
9,100
CEO
George Scangos
Address
225 Binney St
Cambridge
Massachusetts
02142-1031
Cambridge
Massachusetts
02142-1031
Phone
17814642000
Website
www.biogen.com
Ticker Symbol
BIIB
Reporting Currency
USD
Company Description
At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.
One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain..